Good Start Genetics Raises $18 Million For Sequencing-Based Testing

Now with $18 million in hand from a trio of blue chip investors, Good Start Genetics is off to, well, a good start as it readies its panel of preconception genetic disease screening tests for launch into the in vitro fertilization market next year. But ultimately, its goal is clearly to leverage beyond the first set of tests and market.